Repligen ( RGEN) is a biopharmaceutical company focused on the development and commercialization of therapies that harness biological pathways and deliver value to patients and clinicians in the fields of neurology and gastroenterology. This stock is trading up 6.5% to $4.05 in recent trading. Today's Range: $3.81-$4.04 52-Week Range: $2.90-$7.29 Volume: 69,000 Three-Month Average Volume: 211,470 >>22 Biopharma Stocks With Breakout Potential in 2012 From a technical perspective, RGEN is ripping higher here on light volume right off some near-term support at $3.72. This move is quickly pushing RGEN within range of taking out its 200-day moving average of $4.05. Traders should now look for long-biased trades if RGEN can manage to sustain a move or close back above its 200-day at $4.05 with volume that's near or above 211,470 shares. If we get that action soon, then RGEN could easily continue to uptrend back towards its next significant overhead resistance level at $4.72, or even its 50-day moving average of $4.98 in the near future.